在转移EGFR突变肺癌中的STK11遗传变异
Dandan Yin1,2, Xiyi Lu3, Xiao Liang4
1The Second Hospital of Nanjing, Clinical Teaching Hospital of Medical School, Nanjing University, Nanjing, People's Republic of China.
STK11基因变异预测转移EGFR突变肺癌的结果会更差,可能导致对奥西默提尼布的耐药性. 像特拉美丁尼布这样的MEK抑制剂可能会恢复STK11缺乏细胞的敏感性.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮表皮生长因子受体 (EGFR) 突变是肺腺癌的关键驱动因素.
- 越来越多的STK11突变被认为是肺癌中重要的同时发生的变化.
- 在EGFR突变肺癌中,STK11变化的预后和治疗影响仍然不完全理解.
研究的目的:
- 调查STK11遗传变异与转移EGFR突变肺癌患者结果之间的关系.
- 确定STK11的变化是否预测对EGFR氨酸激酶抑制剂 (TKI) 的耐药性,特别是 osimertinib.
- 探索潜在的治疗策略,以克服STK11突变肺癌中奥西默提尼布耐药性.
主要方法:
- 来自cBioPortal和江阴人民医院的临床和基因组数据的回顾性分析.
- 单变量和多变量生存分析,包括倾向性得分匹配 (PSM).
- 实验室细胞培养实验和药物查以评估奥西默提尼布耐药性和识别敏感剂.
主要成果:
- STK11的改变与转移EGFR突变肺癌的预后明显差,即使在PSM之后.
- STK11突变与EGFR突变具有相互排他性,并与对奥西默蒂尼布的耐药性有关.
- STK11功能的丧失与改变的代谢信号和减少的免疫透物相关.
- 特拉美丁尼布 (一种MEK抑制剂) 显示出对STK11缺乏细胞对奥西梅丁尼布的敏感度.
结论:
- 在转移性EGFR突变性肺癌中,STK11遗传变化代表了负面预后因素.
- STK11缺陷有助于奥西默提尼布耐药性,可能通过代谢和免疫路径调节.
- 使用像特拉美丁尼布这样的抑制剂准MEK信号可能提供一种可行的策略,以重新敏感化STK11突变肺癌对奥西默蒂尼布.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Mitogens and the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Ras Gene
Ras is a...
